DiaMedica Therapeutics Inc.
DMACHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeDiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. The $393.3M market capitalization puts DMAC squarely in small-cap range for its industry. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.
Market Cap
$393.3M
Beta
0.97
P/E (TTM)
—
P/E (Fwd)
-8.30
EPS (TTM)
$-0.73
EPS (Fwd)
$-0.88
ROE
-86.5%
ROA
-50.0%
Cash
$51.3M
Total Debt
$212,000
Free CF
-$18.0M
52W Change
74.6%
Annual Financials
Cash vs Debt
With $51.3M in cash and $212K in debt, DMAC maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$18.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -86.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, DMAC has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for DiaMedica Therapeutics Inc. and its sector.